SARCLISA conc perf 100 mg/5ml flac 5 ml
7680675250011
CH-67525
L01FC02
07.16.1.
Reimbursement limitations:
SARCLISA
SARCLISA en association avec le pomalidomide et la dexaméthasone
Le traitement nécessite une garantie de …
1 / 3
google
Details
- Product number
- 6752501
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- isatuximabum 100 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, aqua ad iniectabile, q.s. ad solutionem pro 5 ml.
Articles (1)
Sarclisa 100 mg/5 mL , solution à diluer pour perfusion
Lösung
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
100.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 505.60
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/07/2023
Authorization holder
Sanofi-Aventis (Suisse) SA
1214 Vernier
Authorization information
- Swissmedic authorization number
- 67525
- Drug name
- Sarclisa, solution à diluer pour perfusion
- Galenic form
- KOINF
- ATC Code
- L01FC02
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 18/03/2020
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- SARCLISA conc perf 100 mg/5ml flac 5 ml
- Description (DE)
- SARCLISA Inf Konz 100 mg/5ml Durchstf 5 ml
- Market launch
- 18/03/2020
- Narcotic (BTM)
- No